Skimune® for GvHD
Prediction of Graft-versus-Host Disease post-transplant
Key Facts
About Alcyomics
Alcyomics is a private, revenue-generating biotechnology service provider leveraging its patented Skimune® platform, a human skin explant assay, to predict immunotoxicity and efficacy for pharmaceuticals, cosmetics, and chemicals. Founded on over 30 years of academic research in graft-versus-host disease (GvHD), the company has validated its assay with >80% clinical correlation and now offers highly customizable testing services to help clients reduce development costs and animal testing. Operating from Newcastle upon Tyne, Alcyomics targets the growing market for human-relevant, non-animal testing solutions across multiple sectors including immunology, dermatology, and advanced therapies.
View full company profile